C-EOYZTOR Therapeutics
mTORC1 inhibition, fixed-dose combination, neuroinflammation
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-EOYZ
C-EOYZC-EOYZmTORC1 inhibition, fixed-dose combination, neuroinflammation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
%PDF-1.6 %���� 1 0 obj >stream doi:10.1371/journal.pntd.0009969 Rahsan Erdem, Gwen Ambler, Mohamed Al-Ibrahim, Katarzyna Fraczek, Steven D. Dong, Christopher Gast, Laina D. Mercer, Michael Raine, Sharon M. Tennant, Wilbur H. Chen, Eugenio L. de Hostos, Robert K. M. Choy A Phase 2a randomized, single-center, double-blind, placebo-controlled study to evaluate the safety and preliminary efficacy of oral iOWH032 against cholera diarrhea in a controlled human infection model 10.1371/journal.pntd.0009969 http://dx.doi.org/10.1371/journal.pntd.0009969 2021-12-02 false 10.1371/journal.pntd.0009969 www
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.6 %���� 10994 0 obj > endobj xref 10994 19 0000000015 00000 n 0000000704 00000 n 0000001692 00000 n 0000001940 00000 n 0000002031 00000 n 0000002052 00000 n 0000003884 00000 n 0000003908 00000 n 0000003993 00000 n 0000004112 00000 n 0000004266 00000 n 0000004370 00000 n 0000004476 00000 n 0000004578 00000 n 0000012279 00000 n 0000012303 00000 n 0000082760 00000 n 0000082785 00000 n 0000000918 00000 n trailer > startxref 0 %%EOF 10995 0 obj > >> >> >> endobj 11012 0 obj > stream x�c``�```����� � Ȁ�@1F�� �:�TdU��H��,�z�M�I����Ԅy3L8dN ����*�4Q�F� ��|��a-'�^>t�(N��0 ��rn�]��(� … $9IܑXP ش 8��J L��l�:�`��8=|(�hZ��@�s��������ó�˃V ��� z*ƱB n�BB!�Y (rfp�x;��I+�aH�^��x����MC�}B}������-k �i/hR��9��pLR1��6����|wQ��$�5ő��C��-"ߊ���˥�{��Z���$��볪@ @C?`�4.� Z�e���v��3Ä�����u���� �U����_`2���_��V�c��P��0Z�"V�� ��O69ɵ�m��ij��Pȕ�;5v��)b+�^�y�� ���hx)�m6 5���-�Bl>!y:���)�5i�]q~�gAe����nX� � /U� �,A �}ċ9W�1.n8�C����nTk �$up@+�q�0��fH�e�>]}�qE��v� T�fe��r���n�&ۨ�,,�� �h6H�o'�K��4���[�A wW/��)�s��o����(oї��A�'�-����v … DC80F2 2010-09-10T13:57:23-04:00 Adobe Photoshop CS5 Macintosh / converted from application/vnd.adobe.photoshop to image/tiff derived converted from application/vnd.adobe.photoshop to image/tiff saved xmp.iid:038011740720681192B0C82301DC80F2 2010-09-10T13:57:23-04:00 Adobe Photoshop CS5 Macintosh / xmp.iid:028011740720681192B0C82301DC80F2 xmp.did:018011740720681192B0C82301DC80F2 xmp.did:018011740720681192B0C82301DC80F2 8BIM%8BIM:� printOutputPstSboolInteenumInteClrmpr
Client Challenge JavaScript is disabled in your browser. Please enable JavaScript to proceed. A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.
%PDF-1.4 %���� 5 0 obj > /Type /Annot /Rect [33 690.500000 549.750000 699.500000] >> endobj 6 0 obj > /Type /Annot /Rect [105 608 124.500000 617] >> endobj 7 0 obj > /Type /Annot /Rect [171.750000 608 297.750000 617] >> endobj 8 0 obj > /Type /Annot /Rect [33 585.500000 105 594.500000] >> endobj 9 0 obj > /Type /Annot /Rect [35.2500000 76.2500000 126 85.2500000] >> endobj 10 0 obj > /Type /Annot /Rect [488.250000 63.5000000 548.250000 72.5000000] >> endobj 4 0 obj [5 0 R 6 0 R 7 0 R 8 0 R 9 0 R 10 0 R] endobj 12 0 obj > endobj 13 0 obj [/Pattern /DeviceRGB] endobj 14 0 obj > stream x��{PW��+�
OTR Therapeutics raises $100 million in series A financing - Drug Discovery World (DDW) Drug Discovery World (DDW) About Us | Subscribe Free | Media Info | Contact Us | Log In News Exclusive Content Features Opinion Market Reports Trends & Analysis Start-up Zone DDW eBooks Business & Investment Regulatory Events DDII Events Series Other Events Webinars Resources Magazine Digital Issues Archive Multimedia Videos Podcasts Topic filter: Cancer Research Immunology / Virology & Vaccines Advanced Therapies Neuroscience Multiomics Artificial Intelligence Automation & Robotics Therapeutic Antibodi
--> TOR Therapeutics top of page TOR THERAPEUTICS INC Home Background Our Team For Investors Contact Our Story Our Vision More Use tab to navigate through the menu items. [email protected] TOR THERAPEUTICS Our Mission is Healthy Aging Home: Welcome OUR STORY A Novel Approach Welcome! We are Drs. Jeffrey Melin and Nancy Young, a husband and wife physician team. We founded TOR Therapeutics in 2015 to treat neurodegenerative disease. Our company is developing a novel fixed dose combination of two mTORC1 inhibitors. Our lead focus is to treat patients with Alzheime
%PDF-1.4 %�쏢 %%Invocation: gs -sDEVICE=pdfwrite -dPDFSETTINGS=/printer -dCompatibilityLevel=1.4 -dColorConversionStrategy=/LeaveColorUnchanged -dDownsampleMonoImages=true -dDownsampleGrayImages=true -dDownsampleColorImages=true -dAutoFilterColorImages=true %%+ -dAutoFilterGrayImages=true -dColorImageFilter=/FlateEncode -dGrayImageFilter=/FlateEncode -dCompressFonts=true -dColorImageResolution=150 -dGrayImageResolution=150 -dMonoImageResolution=150 -dNOPAUSE -dQUIET -dBATCH ? ? ? 5 0 obj > stream x���˯�Wv x/���/�q �S��[�~�m�Ȓ�RZV�%:�\@����%��3 h���( @R�L��I� ��&�!@c���l��Lc����ڏsyI��
Full text of "Financial Times , 1997, UK, English" Skip to main content Keep the news in the Wayback Machine. Sign Fight for the Future's letter . Hamburger icon An icon used to represent a menu that can be toggled by interacting with this icon. Internet Archive logo A line drawing of the Internet Archive headquarters building façade. Web icon An illustration of a computer application window Wayback Machine Texts icon An illustration of an open book. Texts Video icon An illustration of two cells of a film strip. Video Audio icon An illustration of an audio speaker. Audio Software ico … thuis said the reforms, which would take immediate effect, would let the state “apply principals in force in the private sector to the control of companies in its possession". He said there was no ques- tion of the state seeking to meddle in the management of public companies. Never- state companies face changes The French Socialist party yesterday estimated the cost of its plan to create 700,000 jobs for young people at FFr35bn ($6bn) to be funded by re-allocation of exist- … s would only be introduced in consul- tation with businesses. He said a unified grant of grtettng job assistance measures costing FFr40,000- FFr50,000 per job would be used to encour- age employers in the private sector to employ 350,000 young people and help cut the 13 per cent jobless rate. Up to 150,000 of these posts could came by allowing those aged under 60 but who had already made 40 years of social security contributions, to retire early. funding for an additional 350 … tably tempered by the increased number of shares in issue. CAPITALISATION SHARE AWARD AND FINAL DIVIDEND The Board has declared a final dividend of 222 cents per share, on account of the year ended 31 March 1997. The dividend will be paid only to those shareholders registered on 30 May 1997 (the record d ate”) who elect, by 12:00 on 27 June 1997. to receive the cash efividend as an alternative to the automatic capitalisation award to shareholders. However, If a cash dividend … ordinary shares. The date of payment of the dividend, posting of capitalisation award shares and listing of the new ordinary shares will be 2 July 1997. Circulars wilt be mailed to shareholders on or about 3 June 1997 2 Jan Smuts Avenue Johannesburg 2001 Republic of South Attica Copies Of the PreUmk&y Report, wftch corrtafo partfcufara of tfw
%PDF-1.7 4 0 obj (Identity) endobj 5 0 obj (Adobe) endobj 8 0 obj > stream x��`�E�?���l�lK�-ɶ�lʒ$D������ I�$T�S�Ѡ�y��,��^7 �����6D�)�TP�㎻����}g6���� �?ya>O�3���Ӧ|f���f�� I�5��F �}]m)ȋ�H�4��j�iM�k �����Ǝ'�7� �R�����M��� ��9 pU��q��˞���% ̸��%W l�^7�b��ڷ�� ����X9�� eu�F"M���y��5�>5ޏ�����y3��z,�t����ϛq��\�<> ���E�c�0 �w:�ߴpFS{���!���[V7J��4S eߪ�*��������u{�~Z|�&�T�㮚�@_�騂IF�i�o՝҉�:c �`�Q ��~���uL�b�dPɿ� ���/�����Ȃ�eIDi �Ŷ�e�;@� ]��s����7u %�Jy* $��ѷɣ�B������B��+a�?�Ht�����] �Q�@w��{>�e����(S�+� ;��������N���x�f!A�'��V�?��J���9�0a> ��cέ�LO�z���
EX-99.1 2 a2023aug_contextxcorppre.htm EX-99.1 a2023aug_contextxcorppre August 2023 Corporate Presentation Advancing Medicines for Solid Tumors Important Notice and Disclaimers Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that reflects the Company’s current views about future events and are subject to risks, uncertainties, assumptions and changes in circumstances that may cause events or the Company’s actual activities or results to differ significantly from those expressed in any forward-looking
Turn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing - Turn Therapeutics Skip to content Turn Therapeutics ($TTRX) to Ring the Closing Bell at Nasdaq GX-03 Pipeline Non-Systemic Medicine Science & Technology Partnerships Press Coverage About Us Investors GX-03 Pipeline Non-Systemic Medicine Science & Technology Partnerships Press Coverage About Us Investors Press Release Turn Therapeutics Secures $75 Million Investment Commitment Tied to Public Listing By Turn Therapeutics December 12, 2024 ESTLAKE VILLAGE, Calif.–( BUSINESS WIRE )–Turn Thera … University with a BS in Biology, and with Honors from Duke Medical School. His residency at Rush Medical Center focused on sports medicine, specializing in knee & shoulder surgery. Linkedin Bradley Burnam Chief Executive Officer & Founder Bradley Burnam, Founder & CEO, developed PermaFusion®, a patented drug delivery system, to combat his hospital-acquired skin infection. This innovation led to Hexagen™ Wound Dressing, Turn’s flagship product. Burnam, a sel … or the latest updates from our Founder’s Blog. First Name Last Name Email Submit Sign Up for Updates Enter your information to receive the latest product updates and news from Turn Therapeutics. First Name Last Name Email Submit
Our Portfolio - T1D Fund: A Breakthrough T1D Venture Donor Login Contact Us Breakthrough T1D About Investment Strategy Portfolio Our Team News Donor Login Get in Touch Our Portfolio Show All Active Portfolio Exited Portfolio Aera Therapeutics Approach: Aera Therapeutics is developing lipid nanoparticle-based in vivo CAR-T therapies designed to modulate the immune system through B cell depletion Strategic Area: Immune Modulation Adaxion Therapeutics Approach: Adaxion Therapeutics is developing innovative treatments for immune-mediated and inflammatory diseases using its proprietary ADAx deimmun … and prevent hypoglycemic events Strategic Area: Metabolic Control About the T1D Fund: A Breakthrough T1D Venture Launched in 2016 as a wholly owned subsidiary of Breakthrough T1D, the T1D Fund is the first scaled venture fund established to catalyze the development of T1D cure-oriented therapies through investments. The Fund co-invests with venture capital firms and biopharma companies in support of early-stage companies pursuing disease-modifying therapies and potential cure … essionals, working in partnership with an independent Investment Committee, the Fund leverages its vast research, clinical, regulatory, and medical affairs network on behalf of its portfolio companies. Funded through charitable contributions from donors and from Breakthrough T1D itself, the Fund makes investments in biotech companies and reinvests returns into new investments, thereby extending the impact of its donors’ contributions. About Investment Strategy Portfolio
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Torrey Pines Investment 0 Skip to Content About Team Portfolio News Contact Open Menu Close Menu About Team Portfolio News Contact Open Menu Close Menu About Team Portfolio News Contact Investing in life-sciences, naturally Helping our companies, achieving growth, building value and realizing wealth. About Torrey Pines Investment Torrey Pines Investment LLC, founded in 2012 in San Diego, CA, is a specialty life-science investment company. Torrey Pines has a team of investment professionals with extensive experience in entrepreneurship, venture capital and operations. Our firm supported
%PDF-1.6 %���� 15151 0 obj > endobj 15168 0 obj >/Filter/FlateDecode/ID[ ]/Index[15151 24]/Info 15150 0 R/Length 84/Prev 5152506/Root 15152 0 R/Size 15175/Type/XRef/W[1 2 1]>>stream h�bbd``b`Y $�AD�`��3�`��JA�� V��"�A��@�� Ī�U�k?���Y ����cG���* endstream endobj startxref 0 %%EOF 15174 0 obj >stream h�b```a``���� � ���� ��(h(̨�f����lb$,(d���(�b�(d�j � �j$���j 5�92tMxqk֡�rr���9���l��8��}`����S�(�9��z���S) ��rT��Eݵ����MK�ĜR0�2�>7��n�R���&�?+�����U=���1Xaƿ����ՓyxK�Ey_�P��;D�U��9f���}�X�>'�GK�^�}��&�H���/ �Xp��O>�L\Kk�fz@F��E�T�v�b��E� | q,�K�\'y�L��:驡�O�)}'^y … �6ն�8xz�"R�v���7[.���� �ua̼E� ���Gx �,�q��ޭ�3����?6�f�.#Cz�oy@����'"{�rFp$���ub(�Hö�( ���a�� ��cwn�N�������R_�� �>�Ec�=[\�9�-�~UͰ�s�IƮ�fcz�:�� ��|в�oxש�{D� V|�-�3J� !��^�|�������� b%��,�? c��.ju���'�O5ɚ6/&�3��T�:�����q� �s�b�� �I˩�J� ��Dn ���t�K��#�絽� D�Ko5E^��2�h +�I���FrǮɛ�[ e���=a��0��U�%% �X����Q�p�>`�D��zB�:2.5�v���߮m:N_Ҙ�c��*B�o��n��a�W��G� }��~� ku�J�v��\d��lLvA+-�TO�v���(c�|�!��48f(���L+%�i��"٘ߢo>7=�W��K�� �8P�wG8C��Q … 1:46:50-04:00 2010-04-13T11:46:50-04:00 Adobe Acrobat 9.0 Paper Capture Plug-in application/pdf uuid:f1fef805-f64f-41ee-bb8e-56b8081c7218 uuid:f248fcc8-f30f-4751-9e7b-e1203d73ba13 endstream endobj 770 0 obj >stream h�4�;N�@D��x�7 i� ! Bd��"���ۃ\���ru��rmm;�������m������he�� ϡ�~���BU�R�RU�` �SZM ʔ���5q�@�,�[��q���vY��|:Ƚ%]odh�HD���?���E]�]>>����}|�5�x��� >stream h�d�� �0�_�on�;�C������V,��e�A/��#��m[ .Ǵ .6 +��J�T�����_������~���5���5��|��˖���@��i
TCG Portfolio | Transforming Bold Science into Breakthroughs Skip to content Main Menu Meet TCG Overview Cultivating New Frontiers of Science TCG Team Our Portfolio In the News Join our Ecosystem Contact Us Investor Login Contact Us Investor Login Transforming Bold Science into Therapeutic Breakthroughs Our Portfolio The TCG team partners with portfolio founders to operationalize research into clinically productive companies, supporting them from inception or asset acquisition to partnership or exit. Across its two-decade history, TCG has started/invested in 55 companies leading to 18 exits, g … ic Fibrosis therapies, using modern screening and structural biology methods to apply this strategy beyond CF. Visit NILO Therapeutics is an early-stage biotech company developing groundbreaking therapies for autoimmune and inflammatory diseases. Visit Surrozen is discovering and developing novel regenerative medicines with a focus on unlocking the powerful self-renewal properties of the body through specific control of the Wnt signaling pathway. The Wnt pathway plays a criti … unded with the mission to create new cancer therapeutics through the innovative application of unexploited insights in immunology. Flexus Biosciences was acquired by Bristol-Myers Squibb in April 2015 for $1.3B. Visit ORIC is a small molecule oncology company focused on combating the growing resistance problem to current molecularly targeted drugs. NASDAQ : ORIC Visit Tenaya is focused on creating therapeutics for heart failure patients. Tenaya seeks to address heart disease … om our team and portfolio The Column Group Raises Over $400 Million For Its New Fund, TCG Labs-Soleil The Column Group launches a novel ‘venture-biotech’ model, creating an integrated ecosystem to exclusively fund, discover, and develop single-asset biologic therapies. View all News Portfolio News 06.24.26 Remix Therapeutics™ and Passage Bio Announce Merger Agreement 06.22.26 Nura Bio Completes $73.8M Series B Financing and Advances Pipeline of SARM1 Inhibitors 06.04.26 Kally
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
Torsemide Tablets Ip 20 Mg Dry Or Cool Dry Or Cool at Best Price in Dewas | Care India Medical Agency Search Login Sign Up Tradeindia Common Medicines & Drugs Pharmaceutical Tablets Torsemide Tablets Ip 20 Mg Dry Or Cool Price: Get Latest Price In Stock Send Inquiry Product Specifications Physical Form Tablets Dosage as per doctor guidelines Dosage Guidelines as per doctor guidelines Suitable For Suitable For All Storage Instructions dry or cool Payment Terms Telegraphic Transfer (T/T), Cash in Advance (CID), Cash Advance (CA) Delivery Time 1 Days Sample Available Yes Sample Policy Contact … Send Inquiry Hydroquinone, Tretinoin And Mometasone Furoate Cream Twinkle Cream Application: Control Virus Send Inquiry ORS Electroford Iron Supplement Powder - 25 Sachet Pack | Easy-to-apply Spray, Supports Pigeon Health, Enhances Nutrient Balance Send Inquiry Protichem Dha Alkem Powder With 18 Month Shelf Life Efficacy: Promote Healthy & Growth Send Inquiry Torsemide Tablets Ip 20 Mg Dry Or Cool Send Inquiry Cetirizine HCl, Paracetamol & Phenylephrine HCl Suspension
Companies - Cure Ventures Skip to content People Companies Approach About Menu Toggle Overview News Community Careers Contact Main Menu People Companies Approach About Menu Toggle Overview News Community Careers Contact Companies with Curative Ambition Breakthrough is Just the Beginning for Our Entrepreneurs Meet a Member of Our Family Tree Dr. Milenko Cicmil, CEO of Tasca Therapeutics As a veteran in the world of drug discovery, the beginnings of my partnership with Cure Ventures and the building of Tasca Therapeutics can be linked back to a single walk in the park with one of the founding pa … hard-to-treat cancers. With their unique properties, our TCEs are adaptable for application across a variety of cancers with high unmet need. Focus/Therapeutic Area: Oncology Stage/Status: Series A Website: https://www.clasptx.com/ View More Crosslink is engineering cancer medicines that conditionally assemble in the tumor microenvironment. Our technology can be adapted to multiple therapeutic modalities, improving safety and efficacy. Focus/Therapeutic Area: Oncology Stage/S
--> TOR Therapeutics top of page TOR THERAPEUTICS INC Home Background Our Team For Investors Contact Our Story Our Vision More Use tab to navigate through the menu items. [email protected] TOR THERAPEUTICS Our Mission is Healthy Aging Home: Welcome OUR STORY A Novel Approach Welcome! We are Drs. Jeffrey Melin and Nancy Young, a husband and wife physician team. We founded TOR Therapeutics in 2015 to treat neurodegenerative disease. Our company is developing a novel fixed dose combination of two mTORC1 inhibitors. Our lead focus is to treat patients with Alzheime
JavaScript is disabled In order to continue, we need to verify that you're not a robot. This requires JavaScript. Enable JavaScript and then reload the page.
%PDF-1.7 %���� 1 0 obj >/Metadata 350 0 R/ViewerPreferences 351 0 R/PageLabels 352 0 R>> endobj 2 0 obj > endobj 3 0 obj >/XObject >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 33 0 R 34 0 R 35 0 R 36 0 R] /MediaBox[ 0 0 612 792] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��}ێ%�q�{���P9�� 4 ���2�XkK�>~f�+y-?���K�$ϩs�ن%�TW&��`0�����._����o��v�ϗ�oo����w�����E^~�� ��&/ֻ����o��˟�ӗ��|�\���}��������2��6�/V�-؋rs:w��s��O_่��w��_��ӗ���?��'w���� �`�8��D��.U�����]��^ ;{�i6a.��sZg �������p�} 3>�Tp��ŅGhĵI�����?���_�P��I��>��=��O�m���͏� … �S}�[(�C��F���iJm�&KZ�TQEb�#�z����eisw}3yV�Ec)n01�x���t���/�i�V1�Py��� �岜RFp�#� �=�:F���ζ�Q���mé ����1�x�DB98�k9^N�d^ �#Ҭ)�¹'���M�ř�S�� ?�##+�2 �_�A �s�?�z�+ [�ps�i��U'�w1;p)�s������?�����_� Y��Ӛ �к�E����9'�n�� �$���A���w��H4k� {ҧ�,_S�G�� OJճ";3�+ڱ��Z �:cޥ�����c��BT����"��-�#�0�>��]v������ V�� �\d�����ZKv�6�s���"�$�!�����&� ��U�`�ň=9�ߚ�b;�;x�V�ov ?Z[G�u�pG���֒�D����Os]�� �z��,�q� �m:�Ĺ�%c�ݩ��� �QZ(���Z]��|�7��c�-������t.�/8)�A�H�8
%PDF-1.7 %���� 76 0 obj > endobj 93 0 obj >/Filter/FlateDecode/ID[ ]/Index[76 37]/Info 75 0 R/Length 91/Prev 133854/Root 77 0 R/Size 113/Type/XRef/W[1 3 1]>>stream h�bbd```b``Z"'�� �� L�HfG0)�����u`�s��t��0 �x ���DJ >stream h�b```�F Ad`��0p\x'�na``�>������#~(f`�``�`�Ǥ�$�� h�r�0�R&{&�{���b� ����w��30�4�Mac`�� ex `" endstream endobj 77 0 obj >/Metadata 4 0 R/Pages 74 0 R/StructTreeRoot 8 0 R/Type/Catalog/ViewerPreferences 94 0 R>> endobj 78 0 obj >/MediaBox[0 0 595.32 841.92]/Parent 74 0 R/Resources >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI]/XObject >>>/Rotate … 4{B�/�5�� endstream endobj 4 0 obj >stream Microsoft® Word for Microsoft 365 application/pdf LEYDORF, Deborah Mary Microsoft® Word for Microsoft 365 2022-06-22T17:14:10+02:00 2022-06-23T10:08:28+02:00 2022-06-23T10:08:28+02:00 uuid:D2D1DAE9-46BB-490C-AA04-A07A1475A553 uuid:253359c0-fc5c-41b9-9fcd-fe4848088dcb endstream endobj 5 0 obj >stream h�27Q0P���w�/�+Q0���L)�6� )��X��ʂT�����b;;�&w endstream endobj 6 0 obj >stream h�27U0P���w,-��/��q�t�r�QpIM�/J�P�M,���w.JM,���sI,
%PDF-1.7 %���� 2714 0 obj > endobj xref 2714 26 0000000016 00000 n 0000005115 00000 n 0000005310 00000 n 0000005347 00000 n 0000008581 00000 n 0000009128 00000 n 0000009167 00000 n 0000009763 00000 n 0000009878 00000 n 0000009991 00000 n 0000010454 00000 n 0000011451 00000 n 0000012267 00000 n 0000013088 00000 n 0000013872 00000 n 0000014641 00000 n 0000015241 00000 n 0000015895 00000 n 0000016491 00000 n 0000022606 00000 n 0000025256 00000 n 0000060853 00000 n 0000060894 00000 n 0000064490 00000 n 0000004896 00000 n 0000000831 00000 n trailer ]/Prev 888053/XRefStm 4896>> startxref 0 %%EOF 273 … ��5k��yݭ���ǯg��^y�kEk�����l�D_p߶������7Dm����o꿻1m��l�{��Mś� n�L�l� >stream application/pdf logos_CENTRES_NB_GHC_1 Adobe Illustrator CC 2017 (Macintosh) 2020-03-25T17:21:22+01:00 2020-03-25T17:22:49+01:00 2020-03-25T17:22:49+01:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:0c85601b-a672-41bf-8877-732847e61d46 uuid:44174817-f784-974c-93af-8bd238010e27 uuid:9aa5e26d-c29c-1a48-a3b6-3ca37ca56fe2 xmp.did:038011740720681183D1909C0200B000 uuid:65E6390686CF11DBA6E2D8 … 5bad70f7504 xmp.did:489b8ce0-642e-4758-9ce5-a45ed72a5f7e default converted from application/x-indesign to application/pdf Adobe InDesign CC 14.0 (Macintosh) / 2020-06-19T09:31:48+02:00 saved xmp.iid:cd73c463-9e3a-4dd7-ac04-76b99bbf4cf6 2020-10-24T12:48:06+02:00 Adobe Illustrator 24.3 (Macintosh) / saved xmp.iid:6ec07536-995c-4e4b-be21-dd3156d40585 2021-04-08T14:18:23+02:00 Adobe Illustrator 25.2 (Macintosh) / application/pdf GHC_WorkingPaper26_Figures-01.a Adobe PDF library 1 … 5bad70f7504 xmp.did:489b8ce0-642e-4758-9ce5-a45ed72a5f7e default converted from application/x-indesign to application/pdf Adobe InDesign CC 14.0 (Macintosh) / 2020-06-19T09:31:48+02:00 saved xmp.iid:cd73c463-9e3a-4dd7-ac04-76b99bbf4cf6 2020-10-24T12:48:06+02:00 Adobe Illustrator 24.3 (Macintosh) / saved xmp.iid:c6f4313c-315b-4462-bc41-6ca3ef92d040 2021-04-08T14:58:43+02:00 Adobe Illustrator 25.2 (Macintosh) / application/pdf GHC_WorkingPaper26_Figures-02 Adobe PDF library 15. … &�Pc�L 7�8 �njXf��qa�H��TĂ �P��J���Ph�Y��&� ��4��c^ ��^ ��'@���8> >stream application/postscript GRADUATE_LOGO_GE 2013-07-30T11:48:01+02:00 2013-07-30T11:48:01+02:00 2013-07-30T11:48:01+02:00 Adobe Illustrator CS6 (Macintosh) xmp.iid:0380117407206811822AD6EC7D5A8952 xmp.did:0380117407206811822AD6EC7D5A8952 uuid:5B20892493BFDB11914A8590D3150
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ